- Home
- HY vs PHAT Comparison
HY vs PHAT Comparison
Compare HY & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HY
- PHAT
- Stock Information
- Founded
- HY 1991
- PHAT 2018
- Country
- HY United States
- PHAT United States
- Employees
- HY N/A
- PHAT N/A
- Industry
- HY Construction/Ag Equipment/Trucks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- HY Industrials
- PHAT Health Care
- Exchange
- HY Nasdaq
- PHAT Nasdaq
- Market Cap
- HY 717.9M
- PHAT 640.9M
- IPO Year
- HY N/A
- PHAT 2019
- Fundamental
- Price
- HY $36.02
- PHAT $9.74
- Analyst Decision
- HY Strong Buy
- PHAT Strong Buy
- Analyst Count
- HY 1
- PHAT 5
- Target Price
- HY $70.00
- PHAT $16.40
- AVG Volume (30 Days)
- HY 71.0K
- PHAT 1.0M
- Earning Date
- HY 08-05-2025
- PHAT 08-07-2025
- Dividend Yield
- HY 4.00%
- PHAT N/A
- EPS Growth
- HY N/A
- PHAT N/A
- EPS
- HY 1.26
- PHAT N/A
- Revenue
- HY $3,950,600,000.00
- PHAT $114,039,000.00
- Revenue This Year
- HY N/A
- PHAT $194.40
- Revenue Next Year
- HY $2.55
- PHAT $103.23
- P/E Ratio
- HY $29.65
- PHAT N/A
- Revenue Growth
- HY N/A
- PHAT 1049.82
- 52 Week Low
- HY $34.13
- PHAT $2.21
- 52 Week High
- HY $69.28
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- HY 32.53
- PHAT 61.57
- Support Level
- HY $35.50
- PHAT $8.03
- Resistance Level
- HY $42.33
- PHAT $10.09
- Average True Range (ATR)
- HY 1.61
- PHAT 0.66
- MACD
- HY -0.73
- PHAT 0.06
- Stochastic Oscillator
- HY 5.75
- PHAT 85.89
About HY Hyster-Yale Materials Handling Inc.
Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.